Update on intravitreal injections

Techniques in Ophthalmology

Volumn 6, Issue 3, 2008, Pages 83-87

  Principe, Andre H ^a,b,c   Chow, David R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CIDOFOVIR; POVIDONE IODINE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

ANESTHESIA; ANTISEPSIS; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; GLAUCOMA; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINITIS; REVIEW; UVEITIS; VEIN OCCLUSION; VITREOUS HEMORRHAGE;

EID: 67650329880     PISSN: 15421929     EISSN: 15421937     Source Type: Journal    
DOI: 10.1097/ITO.0b013e3181890349     Document Type: Review

References (17)

1. Ohm J. Ü ber die behandlung der netzhautablösung durch operative entleerung der subretinalen flüssigkeit und einspritzung von luft in den glaskörper. Albrecht von Graefes Arch Ophthalmol. 1911;79:442-450.
2. Stone EM. A very effective treatment for neovascular macular degeneration. N Engl J Med. 2006;355(14): 1493-1495.
3. Ranson NT, Danis RP, Ciulla TA, et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol. 2002;86(5):527-529.
4. Jager RD, Aiello LP, PAtel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5): 676-698.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
7. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007; 114(2):246-252.
8. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2007 [Epub ahead of print].
9. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27(8):1044-1047.
10. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for the treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24(5):587-611.
11. Frenkel RE, Mani L, Reyes A. Complications of a surgeon's initial intravitreal injections. In: Investigative Ophthalmology & Visual Science (E-Abstract). Fort Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2008.
12. Dahl DE, Dahl T, Lane G. Does lidocaine gel decrease the effectiveness of a povidone-iodine prep? In: Investigative Ophthalmology & Visual Science (E-Abstract). Fort Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2008.
13. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery. An evidence-based update. Ophthalmology. 2002;109:13-26.
14. Ta CN, Egbert PR, Singh K, et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacine prophylaxis for cataract surgery. Ophthalmology. 2002; 109:2036-2041.
15. Bhavsar AR. A consecutive series of 1,000 intravitreous injections without topical antibiotic prophylaxis. In: Invest igative Ophthalmology & Visual Science (E-Abstract). Fort Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2008.
16. Coffee RE, Hubschman JP, Schwartz SD. Experimental model of intravitreous injection techniques. In: Investigative Ophthalmology & Visual Science (E-Abstract). Fort Lauderdale, FL: Association for Research in Vision and Ophthalmology; 2008.
17. Rodrigues EB, Meyer CH, Grummann A Jr, et al. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol. 2007;143(6):1035-1037.